GH · XBRL financial data

Guardant Health financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	287	374	450	564	739	982
Revenue from contracts with customers	—	—	—	564	739	982
Cost of goods and services sold	—	—	—	227	290	349
Research and development	150	263	374	367	348	364
General and administrative	193	207	164	156	180	211
Operating income (loss)	(255)	(411)	(544)	(565)	(444)	(437)
Interest income	10	4	6	35	54	34
Interest expense	5	3	3	3	3	4
Other income (expense)	4	25	(13)	53	(43)	(10)
Income tax expense (benefit)	0	0	1	1	1	(1)
Net income (loss)	—	(385)	(655)	(479)	(436)	(416)
Earnings per share, basic USD per share	(2.60)	(4.00)	(6.41)	(4.28)	(3.56)	(3.32)
Earnings per share, diluted USD per share	(2.60)	(4.00)	(6.41)	(4.28)	(3.56)	(3.32)
Weighted average shares, basic millions of shares	98	101	102	112	123	125
Weighted average shares, diluted millions of shares	98	101	102	112	123	125

Fiscal years (GH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	833	492	142	1,134	526	378
Marketable securities	962	441	870	35	314	823
Marketable securities, non-current	247	698	0	—	—	—
Accounts receivable	53	98	97	89	110	138
Inventory	23	31	52	62	71	86
Prepaid and other current assets	17	53	32	28	34	41
Total current assets	1,888	1,114	1,192	1,347	1,055	1,466
Property and equipment, net	63	124	168	145	137	146
Right-of-use asset	37	189	174	158	142	159
Goodwill	3	3	3	3	3	77
Total assets	2,272	2,204	1,610	1,786	1,486	2,014
Accounts payable	7	18	69	52	39	54
Accrued liabilities	23	45	176	188	68	78
Total current liabilities	67	195	193	206	226	303
Lease liability, non-current	42	226	210	186	164	178
Total liabilities	916	1,559	1,550	1,628	1,625	2,113
Accumulated deficit	(607)	(1,008)	(1,662)	(2,142)	(2,578)	(2,995)
Total stockholders' equity	1,298	645	60	159	(140)	(99)
Total liabilities and equity	2,272	2,204	1,610	1,786	1,486	2,014
Common shares outstanding (cover page) millions of shares	100	102	103	122	123	131

Fiscal years (GH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	(385)	(655)	(479)	(436)	(416)
Stock-based compensation	144	151	95	91	140	166
Depreciation and amortization	16	22	36	43	42	40
Net cash from operating activities	(104)	(209)	(309)	(325)	(240)	(185)
Purchases of property and equipment	36	75	77	20	35	48
Net cash from investing activities	(617)	(63)	150	840	(261)	(627)
Proceeds from issuing common stock	356	0	0	493	0	257
Share repurchases	0	—	—	0	0	45
Net cash from financing activities	1,410	(67)	(189)	477	(1)	671
Net change in cash	690	(341)	(350)	992	(504)	(140)

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Guardant Health	1,053	335	(58)*	134.2M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	70	264	33*	96.1M	—	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026
Caris Life Sciences	not reported	275	not reported	286.8M	—	Q3 FY26 10-QSep 30, 2026
Exact Sciences	956	878*	152*	190.9M	—	Q4 FY25 10-KDec 31, 2025
BillionToOne	562	123	13*	not reported	—	Q3 FY26 10-QSep 30, 2026
Quest Diagnostics	797	3,097	611*	110.0M	—	Q3 FY26 10-QSep 30, 2026
GRAIL	56	45	(81)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Labcorp Holdings	262	3,810	564*	81.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.